Serum Pepsinogen After H. Pylori Eradication

Helicobacter Pylori Eradication Clinical Trial

Official title:

Serum Pepsinogen After Helicobacter Pylori Eradication for the Gastric Cancer Prevention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03924375
• Other study ID #: SCH-HP-2019
• Status: Completed
• Start date: March 15, 2019
• Est. completion date: May 31, 2020

Study information

• Verified date: July 2020
• Source: Soonchunhyang University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Helicobacter pylori has been recognized as a major pathogen in gastric carcinogenesis. Current guidelines recommend the H. pylori "test-and-treat" strategy for the purpose of primary and secondary gastric cancer prevention. Considering the "point of no return" theory, however, H. pylori eradication cannot reduce the risk of gastric cancer in subjects with gastric atrophy and intestinal metaplasia. The intragastric hypoacidic environment is associated with the risk of intestinal-type gastric cancer development. Recently, the secretory ability of the stomach can be measured using the serum pepsinogen (PG) assay.

Description:

This study aimed to evaluate the change of serum PGs after H. pylori eradication success and identify the optimal timing of eradication.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 31, 2020
• Est. primary completion date: March 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• Gastroscopy can be performed

• Serologic markers including serum pepsinogen can be measured

Exclusion Criteria:

• Age < 20 or > 70 years

• Anemia (serum hemoglobin level < 10 g/dL)

• Severe systemic disease

• Advanced chronic liver disease

• Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics

• History of H. pylori eradication

• History of gastric surgery

• Recent history of upper gastrointestinal bleeding

Related Conditions & MeSH terms

• Helicobacter Pylori Eradication

Locations

Country	Name	City	State
Korea, Republic of	Digestive Disease Center, Soonchunhyang University Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Soonchunhyang University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum pepsinogen change after H. pylori eradication	Serum pepsinogen recovery	after 8 weeks